Known targets — ChEMBL curated mechanism
HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7SIGMAR1
The experimentally established mechanism targets of Levofenfluramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 1.00 |
| ▸ | HTR2B known ✓ | P41595 | 4/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.64 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.57 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.43 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.43 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.43 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexfenfluramine SCHEMBL16706 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL16215 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Dexfenfluramine SCHEMBL15669714 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL29447403 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Dexfenfluramine SCHEMBL29499611 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Levofenfluramine SCHEMBL162006 | 1.00 | SLC6A4 (1.00) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL23724055 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL11140094 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Fenfluramine SCHEMBL39491 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C | |
| Levofenfluramine SCHEMBL30951308 | 0.98 | SLC6A4 (0.97) | SLC6A4SIGMAR1HTR2AHTR2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558326-B2 | Method for treating epilepsy | XENON PHARMACEUTICALS INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| EP-4293009-B1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | ZOGENIX INTERNATIONAL LTD (GB) | 2025-06-11 | — | — | EP | disclosed |
| EP-3800177-B1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | ZOGENIX INTERNATIONAL LTD (GB) | 2025-01-29 | — | — | EP | disclosed |
| EP-4395753-A1 | FENFLURAMINE FOR TREATMENT OF DEMYELINATING DISEASES AND CONDITIONS | Zogenix International Limited (GB) | 2024-07-10 | — | — | EP | disclosed |
| EP-3829558-B1 | METHOD FOR TREATING EPILEPSY | XENON PHARMACEUTICALS INC (CA) | 2024-07-03 | — | — | EP | disclosed |
| EP-3340971-B1 | METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE | ZOGENIX INTERNATIONAL LTD (GB) | 2024-03-13 | — | — | EP | disclosed |
| EP-4293009-A2 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | Zogenix International Limited (GB) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023101866-A1 | FENFLURAMINE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH SPREADING DEPOLARIZATION | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-06-08 | — | — | WO | disclosed |
| US-11634377-B2 | Fenfluramine compositions and methods of preparing the same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-04-25 | — | — | US | disclosed |
| WO-2023034115-A1 | FENFLURAMINE FOR TREATMENT OF DEMYELINATING DISEASES AND CONDITIONS | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023006412-A1 | SIGMA-1 RECEPTOR ACTIVATOR FOR USE IN THE TREATMENT OF A PATHOLOGY ASSOCIATED WITH WFS1 MUTATION | UNIVERSITÉ DE MONTPELLIER (FR) | 2023-02-02 | — | — | WO | disclosed |
| CN-115350168-A | Methods of treating Lennox-Gastaut syndrome using fenfluramine | 周格尼克斯国际有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-115192575-A | Methods of treating Lennox-Gastaut syndrome using fenfluramine | 周格尼克斯国际有限公司 | 2022-10-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634377-B2 | Fenfluramine compositions and methods of preparing the same | FAAH, FAAH2, TPH1 | SIGMAR1 1220/4885HTR2A 34/4885HTR2B 35/4885 |
| US-12558326-B2 | Method for treating epilepsy | PNMT, SLC6A1, CPT1B | SIGMAR1 2174/4885HTR2A 239/4885HTR2B 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.